SECARE Stock Overview
Develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in Sweden, the United Kingdom, Rest of Europe, North America, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SECARE passed our risk checks.
Swedencare AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 41.14 |
| 52 Week High | SEK 69.12 |
| 52 Week Low | SEK 32.56 |
| Beta | 0.92 |
| 11 Month Change | -11.45% |
| 3 Month Change | -22.38% |
| 1 Year Change | 17.34% |
| 33 Year Change | -68.79% |
| 5 Year Change | 192.19% |
| Change since IPO | 1,042.78% |
Recent News & Updates
Recent updates
Does Swedencare (STO:SECARE) Deserve A Spot On Your Watchlist?
Apr 29
Swedencare (STO:SECARE) Seems To Use Debt Quite Sensibly
Dec 20Here's Why We Think Swedencare (STO:SECARE) Might Deserve Your Attention Today
Nov 20With EPS Growth And More, Swedencare (STO:SECARE) Makes An Interesting Case
Aug 21Swedencare (STO:SECARE) Has A Pretty Healthy Balance Sheet
Jul 03Should You Be Adding Swedencare (STO:SECARE) To Your Watchlist Today?
Apr 06Analysts Just Published A Bright New Outlook For Swedencare AB (publ)'s (STO:SECARE)
Feb 16Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?
Dec 28A Look At The Fair Value Of Swedencare AB (publ) (STO:SECARE)
Dec 06Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet
Oct 24With EPS Growth And More, Swedencare (STO:SECARE) Is Interesting
Sep 12Calculating The Fair Value Of Swedencare AB (publ) (STO:SECARE)
Aug 19Broker Revenue Forecasts For Swedencare AB (publ) (STO:SECARE) Are Surging Higher
Jul 28Industry Analysts Just Made A Substantial Upgrade To Their Swedencare AB (publ) (STO:SECARE) Revenue Forecasts
Jul 01Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet
Jun 29Shareholder Returns
| SECARE | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.6% | -1.0% | -0.8% |
| 1Y | 17.3% | 61.0% | 23.8% |
Return vs Industry: SECARE underperformed the Swedish Pharmaceuticals industry which returned 61% over the past year.
Return vs Market: SECARE underperformed the Swedish Market which returned 23.8% over the past year.
Price Volatility
| SECARE volatility | |
|---|---|
| SECARE Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: SECARE has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SECARE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 559 | Hakan Lagerberg | www.swedencare.com |
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in Sweden, the United Kingdom, Rest of Europe, North America, Asia, and internationally. The company offers animal nutritional supplements, treats, and grooming products under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and support and solutions for the veterinary community under the Stratford Animal Health name. It also provides pet health supplements under the NaturVet, VETCLASSICS, and NutriScience name; pet supplements, vitamins, dental care, ear cleaners, pilling agents, and topicals under the Pet MD name; and vet-formulated pet care products under the VetWELL name.
Swedencare AB (publ) Fundamentals Summary
| SECARE fundamental statistics | |
|---|---|
| Market cap | SEK 6.54b |
| Earnings (TTM) | SEK 76.10m |
| Revenue (TTM) | SEK 2.47b |
85.9x
P/E Ratio2.6x
P/S RatioIs SECARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SECARE income statement (TTM) | |
|---|---|
| Revenue | SEK 2.47b |
| Cost of Revenue | SEK 1.06b |
| Gross Profit | SEK 1.41b |
| Other Expenses | SEK 1.33b |
| Earnings | SEK 76.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 57.07% |
| Net Profit Margin | 3.08% |
| Debt/Equity Ratio | 17.8% |
How did SECARE perform over the long term?
See historical performance and comparison